Oddity Tech (NASDAQ: ODD) introduced Methodiq, a medical‑telehealth platform that pairs AI‑driven computer‑vision diagnostics with a library of 28 core products and more than 100 personalized treatment plans for acne, hyperpigmentation and eczema. The platform, which went live on November 18, 2025, allows users to receive prescription‑grade skincare without an in‑person visit, leveraging the company’s existing 60‑million‑user digital ecosystem to scale the service quickly.
The launch taps into a sizable opportunity, but the U.S. medical‑grade skincare market is projected to reach $55.59 billion by 2032, not the $113 billion figure cited in the original article. The platform targets roughly 50 million Americans with acne, 30 million with eczema, and an estimated 30 million with hyperpigmentation—figures that underscore the breadth of the potential customer base.
Oddity’s financial performance in the first half of 2025 provides context for the new venture. Net revenue rose 27% YoY to $268 million in Q1 and 25% YoY to $241 million in Q2, reflecting strong demand for its beauty brands IL MAKIAGE and SpoiledChild. Management expects Methodiq to add a new, scalable revenue stream that will complement the company’s direct‑to‑consumer foundation.
Investor reaction to the announcement was muted. Shares fell to a seven‑month low following the launch, indicating skepticism about the company’s ability to monetize the new medical‑grade segment amid regulatory uncertainty and intense competition from established dermatology platforms.
CEO Oran Holtzman said the platform “leverages our AI and data science expertise to serve a large, underserved market of chronic skin conditions.” He added that the company’s technology and direct‑to‑consumer model position it to disrupt the medical‑skincare space and drive long‑term growth.
The Methodiq launch represents a strategic diversification that could unlock significant upside if the company can navigate headwinds such as regulatory hurdles and margin pressure. In the short term, the market’s cautious response suggests that investors are weighing the risks of entering a highly regulated, competitive arena against the potential for high‑margin growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.